CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its ...

Tempus AI Inc. (NASDAQ:TEM) is one of BlackRock’s 30 most important AI stocks right now. BlackRock holds a 5.14% stake in the ...

Tempus AI Inc. (NASDAQ:TEM) is one of the 10 worst artificial intelligence stocks under $30 according to short sellers.

・Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

Trading with an implied upside of 60.5% and an RSI of 34.6, Tempus AI, Inc. (NASDAQ:TEM) has emerged as a notable oversold play in the AI sector. In a span of a week, Tempus AI, Inc. (NASDAQ:TEM) made ...

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...

Tempus AI’s TEM strategic focus for 2026 centers on expanding its AI-driven precision medicine platform by scaling the ...

Tempus AI (TEM) may be building one of healthcare's fastest-growing artificial intelligence (AI) platforms, but the stock ...

Tempus AI Inc. (NASDAQ:TEM) is one of the 9 Stocks Stealing the Show. Tempus AI extended its winning streak to a 3rd straight session on Wednesday, surging 13.89 percent to close at $56.41 apiece, as ...

Tempus AI TEM posted another breakout quarter as diagnostics volumes and pricing improved while data partnerships extended visibility. Execution on mix, reimbursement and bookings sets a clearer path ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune ...